Galapagos (NASDAQ:GLPG) has been upgraded from a 'hold' rating to a 'buy' rating by analysts at StockNews.com. Bank of America has also increased its target price for Galapagos from $41.00 to $44.00 and given the company a 'neutral' rating. The stock currently has an average rating of 'hold' and an average target price of $42.00. Galapagos opened at $35.11 on Friday and has a 50-day simple moving average of $39.06 and a 200-day simple moving average of $37.49. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of -15.33, and a beta of 0.27. Several large investors have recently increased or decreased their stakes in the stock. BNP Paribas Financial Markets has increased its stake in Galapagos by 96.4% during the fourth quarter. Galapagos NV is a biopharmaceutical company that focuses on the discovery, development, and commercialization of medicines for high unmet medical needs. Its pipeline products include filgotinib, a JAK1 inhibitor that is currently in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.
Agenus (NASDAQ:AGEN) was upgraded by stock analysts at StockNews.com from a 'sell' rating to a 'hold' rating. The stock traded down $0.03 on Friday, hitting $0.67. The company has a market capitalization of $267.54 million, a price-to-earnings ratio of -0.82, and a beta of 1.28. Insider Garo H. Armen bought 500,000 shares of the stock in a transaction on February 15th. Agenus is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products. Several hedge funds have modified their holdings of AGEN, including Point72 Asset Management, Bank of America Corp, State Street Corp, and BlackRock Inc. 55.36% of the stock is currently owned by institutional investors.